Trimi Health Review

Trimi Health: a price-first play on compounded GLP-1s

Trimi Health is built around one idea: be the cheapest legitimate way to get a compounded GLP-1 shipped to your door. At $99 a month for compounded semaglutide, it undercuts most of the field, and its compounded tirzepatide lands well under the category median of $169. If your decision comes down almost entirely to the monthly number, Trimi is one of the lowest credible quotes you'll find. The trade-off is transparency: Trimi publishes very little about how its program actually runs, so you're trusting the price and the partners behind it more than a deep paper trail.

How the pricing actually works

Trimi uses a flat-rate model, which is the part worth understanding. Most GLP-1 programs raise your bill as you titrate up to higher doses — the more medication you need, the more you pay. Trimi charges the same price at every dose. Semaglutide stays at $99 a month and tirzepatide at its own flat rate regardless of how high you climb. For anyone planning to reach a full therapeutic dose, that structure can save real money over a year compared with a tiered plan that quietly escalates.

Just as important is what's bundled in. Trimi states its pricing is all-inclusive: the medication, your provider consultations, and shipping are all covered by that one monthly figure. It advertises no hidden fees and free overnight shipping — a meaningful detail, since plenty of budget providers post a low headline number and then tack on a separate consult charge or charge extra for faster delivery. With Trimi, the number you see is meant to be the number you pay.

• Compounded semaglutide: $99 per month, flat at every dose
• Compounded tirzepatide: a modestly higher flat monthly rate, also dose-independent
• Included at no extra charge: medication, provider consultations, and free overnight shipping
• No promo gimmick: Trimi doesn't dangle a teaser first-month rate — the low price is just the standing price

The medications and who actually fills them

Trimi offers compounded versions of both major GLP-1 molecules — semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (the one in Zepbound and Mounjaro). These are compounded formulations, not brand-name pens, which is exactly why the price can be this low. That also means they're made by compounding pharmacies rather than the original manufacturers, so the usual compounding caveats apply: formulations and concentrations can vary, and they don't carry the same FDA approval as the branded drugs.

Two pharmacies are named in Trimi's record: VialsRx and Greenwich RX. The clinical side runs through Beluga Health's licensed providers, which is how Trimi reaches all 50 states. That's a genuinely wide footprint — many compounded-GLP-1 programs have gaps where they aren't licensed — and it means most U.S. patients can use Trimi regardless of where they live.

What sets Trimi apart

Two things, really. First, the aggressive flat pricing with everything bundled in — that combination is rarer than it sounds, because most cheap providers make their margin back on dose increases or add-on fees. Second, the nationwide reach through Beluga's provider network, which removes the state-by-state lottery that trips up a lot of low-cost competitors. If you've been quoted over a thousand dollars a month elsewhere for a brand pen, or turned away because a cheaper service wasn't licensed in your state, Trimi's pitch is straightforward: same medication category, much lower flat cost, available where you are.

Where Trimi falls short

The honest weakness is information. Trimi publishes very little about the details of its program — how consultations are structured, what ongoing support or dose adjustments look like, refund or cancellation terms, and the specifics of who is overseeing your care beyond "Beluga's licensed providers." There are no published accreditation details for its compounding pharmacies in the record, and no money-back or satisfaction guarantee is documented. None of that is a red flag on its own, but it means you're buying largely on price and on trust in the named partners, with fewer of the reassurances a more established telehealth brand spells out up front.

Who should choose Trimi

• Budget-driven shoppers for whom the monthly price is the deciding factor
• People planning to titrate to higher doses, who benefit most from flat dose-independent pricing
• Patients in states where pricier or less-licensed providers won't serve them
• Anyone who wants medication, consults, and shipping in one all-inclusive bill with no surprise add-ons

Who should skip it

• Anyone who needs brand-name Wegovy, Ozempic, Zepbound, or Mounjaro — Trimi is compounded only
• Patients who want extensive, well-documented program details and published guarantees before they commit
• People who value high-touch coaching and clearly defined ongoing support over rock-bottom price

Trust and oversight

On the positive side, there are no FDA warning letters on file for Trimi, and care is delivered through Beluga Health's licensed providers across all 50 states, so there is real clinical infrastructure behind it. The limiting factor for our confidence isn't a problem we found — it's the thinness of public detail. With two named pharmacies but no published accreditation, and little documentation of program mechanics, Trimi earns a cautious read rather than a strong endorsement. As with any compounded-GLP-1 service, confirm the current price, the pharmacy, and the provider setup directly before you pay. You can see how we weigh price, transparency, and oversight in our scoring methodology.

The bottom line

Trimi Health does the one thing it set out to do well: deliver compounded semaglutide and tirzepatide at some of the lowest flat, all-inclusive prices in the market, nationwide. If price is your north star and you're comfortable with compounded medication and a lean information trail, it's a strong-value option worth a direct look. If you want brand-name drugs, deep documentation, or a high-support experience, you'll be happier paying more elsewhere.